<DOC>
	<DOCNO>NCT02960204</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled trial involve subject NASH cirrhosis severe portal hypertension ( define HVPG ≥12 mmHg determine central reader assign study ) . Upon successful screening , subject randomize receive either emricasan 50 mg BID , 25 mg BID , 5 mg BID match placebo BID .</brief_summary>
	<brief_title>Emricasan , Oral Caspase Inhibitor , Subjects With Non-Alcoholic Steatohepatitis ( NASH ) Cirrhosis Severe Portal Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Caspase Inhibitors</mesh_term>
	<criteria>Male female subject 18 year old , able provide write informed consent able understand willing comply requirement study . Cirrhosis due NASH exclusion cause cirrhosis ( e.g . chronic viral hepatitis , alcoholic liver disease , etc . ) Compensated cirrhosis OR Decompensated cirrhosis 1 prior significant decompensating event Severe portal hypertension define HVPG ≥12 mmHg Subjects NSBB , nitrate , diuretic , lactulose , rifaximin , statins must stable dose least 3 month prior Day 1 Willingness utilize effective contraception ( male females childbearing potential ) Screening 4 week last dose study drug Evidence severe decompensation Severe hepatic impairment define ChildPugh score ≥10 ALT AST &gt; 5 time upper limit normal ( ULN ) screen Estimated creatinine clearance &lt; 30 mL/min Prior transjugular intrahepatic portosystemic shunt portosystemic bypass procedure Known portal vein thrombosis Symptoms biliary colic , e.g . due symptomatic gallstone , within last 6 month , unless resolve follow cholecystectomy Current use medication consider inhibitor OATP1B1 OATP1B3 transporter Alphafetoprotein &gt; 200 ng/mL History presence clinically concern cardiac arrhythmia , prolongation screening ( pretreatment ) QTcF interval &gt; 500 msec History active malignancy , successfully treat curative intent believe cure Significant systemic major illness liver disease Use control substance ( include inhale injected drug ) nonprescribed use prescription drug within 1 year screening If female : plan known pregnancy , positive urine serum pregnancy test , lactating/breastfeeding Previous treatment emricasan active investigational medication ( except methacetin ) clinical trial within 3 month prior Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>cirrhosis</keyword>
	<keyword>Portal Hypertension</keyword>
	<keyword>Non-alcoholic Steatohepatitis</keyword>
	<keyword>Liver cirrhosis</keyword>
</DOC>